Hologic (NASDAQ:HOLX) Posts Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Hologic (NASDAQ:HOLX) issued its earnings results on Thursday. The medical equipment provider reported $1.04 earnings per share for the quarter, missing the consensus estimate of $1.09 by ($0.05), FiscalAI reports. Hologic had a return on equity of 20.00% and a net margin of 13.18%.The company had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the prior year, the firm earned $0.87 earnings per share. The company’s revenue for the quarter was up 2.5% on a year-over-year basis.

Hologic Price Performance

HOLX stock opened at $74.93 on Friday. The company has a current ratio of 3.75, a quick ratio of 3.06 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $16.73 billion, a PE ratio of 31.22, a P/E/G ratio of 2.13 and a beta of 0.69. Hologic has a 12-month low of $51.90 and a 12-month high of $75.36. The business’s fifty day moving average price is $74.89 and its 200 day moving average price is $70.85.

Key Headlines Impacting Hologic

Here are the key news stories impacting Hologic this week:

• Positive Sentiment: GYN Surgical business showed solid growth, providing a bright spot that can support longer-term revenue expansion if trends continue. HOLX Stock Slips on Q1 Earnings and Revenue Miss, Margins Crash
• Positive Sentiment: Top-line growth was positive year-over-year (roughly +2.5%), showing continued demand across parts of the portfolio despite the quarter’s misses. Hologic Press Release (Q1 FY2026)
• Neutral Sentiment: Company filed an official Q1 release and provided detailed metrics (net margin ~13.8%, ROE ~20.1%) that investors will parse for guidance and margin recovery timelines. Hologic Announces Financial Results for First Quarter of Fiscal 2026
• Neutral Sentiment: Analyst notes and outlook pieces are weighing near-term headwinds vs. portfolio strength; future quarters and any updated guidance will likely be the main driver of sentiment. Examining the Future: Hologic’s Earnings Outlook
• Negative Sentiment: Q1 EPS and revenue missed consensus estimates, a primary reason for the stock reaction as investors reset near-term expectations. Hologic (HOLX) Misses Q1 Earnings and Revenue Estimates
• Negative Sentiment: Gross margin contracted roughly 150 basis points driven by Diagnostics weakness, suggesting margin recovery could take multiple quarters and pressuring near-term profitability. HOLX Stock Slips on Q1 Earnings and Revenue Miss, Margins Crash
• Negative Sentiment: Market reactions and coverage noted shares edging lower after the print, reflecting investor concern until clearer signs of margin stabilization or guidance improvement emerge. Hologic misses Q1 earnings and revenue estimates, shares edge lower

Analyst Upgrades and Downgrades

Several analysts have issued reports on HOLX shares. Stephens cut Hologic from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $78.00 to $76.00 in a report on Wednesday, October 22nd. BNP Paribas Exane cut shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price target on the stock. in a research report on Friday, November 21st. Evercore ISI cut shares of Hologic from an “outperform” rating to an “in-line” rating and cut their price objective for the stock from $79.00 to $78.00 in a research report on Monday, January 5th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $78.00 target price on shares of Hologic in a report on Wednesday, October 22nd. Finally, Raymond James Financial cut shares of Hologic from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. Three analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the stock. According to data from MarketBeat.com, Hologic presently has a consensus rating of “Hold” and an average price target of $79.31.

Hedge Funds Weigh In On Hologic

Several institutional investors have recently bought and sold shares of the company. Balyasny Asset Management L.P. boosted its stake in shares of Hologic by 1,060.1% in the third quarter. Balyasny Asset Management L.P. now owns 1,218,352 shares of the medical equipment provider’s stock valued at $82,227,000 after purchasing an additional 1,113,330 shares during the period. Adage Capital Partners GP L.L.C. acquired a new stake in Hologic during the 2nd quarter worth approximately $48,283,000. Freestone Grove Partners LP purchased a new position in Hologic in the 3rd quarter valued at approximately $46,800,000. Holocene Advisors LP acquired a new position in shares of Hologic in the second quarter worth $24,438,000. Finally, Raymond James Financial Inc. increased its position in shares of Hologic by 52.9% during the second quarter. Raymond James Financial Inc. now owns 567,695 shares of the medical equipment provider’s stock worth $36,991,000 after acquiring an additional 196,507 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.